Hodgkin lymphoma, version 2.2015.

Published

Journal Article

Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment.

Full Text

Duke Authors

Cited Authors

  • Hoppe, RT; Advani, RH; Ai, WZ; Ambinder, RF; Aoun, P; Bello, CM; Benitez, CM; Bierman, PJ; Blum, KA; Chen, R; Dabaja, B; Forero, A; Gordon, LI; Hernandez-Ilizaliturri, FJ; Hochberg, EP; Huang, J; Johnston, PB; Khan, N; Maloney, DG; Mauch, PM; Metzger, M; Moore, JO; Morgan, D; Moskowitz, CH; Mulroney, C; Poppe, M; Rabinovitch, R; Seropian, S; Tsien, C; Winter, JN; Yahalom, J; Burns, JL; Sundar, H; National comprehensive cancer network,

Published Date

  • May 2015

Published In

Volume / Issue

  • 13 / 5

Start / End Page

  • 554 - 586

PubMed ID

  • 25964641

Pubmed Central ID

  • 25964641

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Language

  • eng

Conference Location

  • United States